Palmar plantar erythrodysesthesia differential diagnosis: Difference between revisions
No edit summary |
Mahshid |
||
Line 8: | Line 8: | ||
==References== | ==References== | ||
{{reflist|3}} | {{reflist|3}} | ||
[[Category:Up-To-Date]] | |||
[[Category:Oncology]] | |||
[[Category:Medicine]] |
Revision as of 15:00, 27 November 2017
Palmar plantar erythrodysesthesia Microchapters |
Differentiating Palmar plantar erythrodysesthesia from other Diseases |
---|
Diagnosis |
Treatment |
Palmar plantar erythrodysesthesia differential diagnosis On the Web |
American Roentgen Ray Society Images of Palmar plantar erythrodysesthesia differential diagnosis |
FDA on Palmar plantar erythrodysesthesia differential diagnosis |
CDC on Palmar plantar erythrodysesthesia differential diagnosis |
Palmar plantar erythrodysesthesia differential diagnosis in the news |
Blogs on Palmar plantar erythrodysesthesia differential diagnosis |
Directions to Hospitals Treating Palmar plantar erythrodysesthesia |
Risk calculators and risk factors for Palmar plantar erythrodysesthesia differential diagnosis |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Differential diagnosis
The problem arises in patients after bone marrow transplants, as the clinical and histologic features of PPE can be similar to cutaneous manifestations of acute (first 3 weeks) graft-versus-host disease. It is important to differentiate PPE, which is benign, from the more dangerous graft-versus-host disease. As time progresses, patients with graft-versus-host disease progress to have other body parts affected, while PPE is limited to hands and feet. Serial biopsies every 3 to 5 days can also be helpful in differentiating the two disorders (Crider et al, 1986).